Pharmaceutical immunoglobulin G impairs anti-carcinoma activity of oxaliplatin in colon cancer cells.

Yuru ShangXianbin ZhangLili LuKe JiangMathias KrohnStephanie MatschosChristina Susanne MullinsBrigitte VollmarDietmar ZechnerPeng GongMichael Linnebacher

Published in: British journal of cancer (2021)

The present study demonstrates that pharmaceutical IgG, such as PRIVIGEN® IgG and Tonglu® IgG, can impair the anti-carcinoma activity of oxaliplatin. These data strongly suggest that therapeutic IgG as co-medication might have harmful side effects in cancer patients. The clinical significance of these preclinical observations absolutely advises further preclinical, as well as epidemiological and clinical research.

Keyphrases

cell therapy
healthcare
emergency department
electronic health record
stem cells
big data
machine learning
bone marrow
artificial intelligence
adverse drug